Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and com...
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal a...
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessin...
Abstract Background The identification of new serum b...
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and ...
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and ...
Pancreatic cancer is a highly lethal malignancy with a dismal 5-year survival of less than 5%. The s...
Pancreatic ductal adenocarcinoma (PDAC) suffers from a very poor prognosis because early stages of t...
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessin...
Background: The clinical management of pancreatic cancer is severely hampered by the absence of e...
Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. ...
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the...
Simple Summary Biomarkers for cancer diagnosis, prognosis and prediction are important tools and an ...
AbstractBackgroundCurrently, no suitable biomarkers for the early detection of pancreatic cancer (PC...
<p>PURPOSE: Serum-biomarker based screening for pancreatic cancer could greatly improve survival in ...
Introduction: Pancreatic cancer is a devastating disease, being the seventh cause of cancer-related ...
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal a...
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessin...
Abstract Background The identification of new serum b...
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and ...
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and ...
Pancreatic cancer is a highly lethal malignancy with a dismal 5-year survival of less than 5%. The s...
Pancreatic ductal adenocarcinoma (PDAC) suffers from a very poor prognosis because early stages of t...
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessin...
Background: The clinical management of pancreatic cancer is severely hampered by the absence of e...
Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. ...
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the...
Simple Summary Biomarkers for cancer diagnosis, prognosis and prediction are important tools and an ...
AbstractBackgroundCurrently, no suitable biomarkers for the early detection of pancreatic cancer (PC...
<p>PURPOSE: Serum-biomarker based screening for pancreatic cancer could greatly improve survival in ...
Introduction: Pancreatic cancer is a devastating disease, being the seventh cause of cancer-related ...
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal a...
The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessin...
Abstract Background The identification of new serum b...